These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36164943)

  • 1. Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.
    Hong JY; Cho HJ; Yun KH; Lee YH; Kim SH; Baek W; Kim SK; Lee Y; Choi YL; Kwon M; Kim HS; Lee J
    Cancer Res Treat; 2023 Apr; 55(2):671-683. PubMed ID: 36164943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
    Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
    Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
    Kim SK; Kim JH; Kim SH; Lee YH; Han JW; Baek W; Woo HY; Jeon MK; Kim HS
    BMC Cancer; 2021 Mar; 21(1):336. PubMed ID: 33789622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression-based prediction of pazopanib efficacy in sarcoma.
    Heilig CE; Laßmann A; Mughal SS; Mock A; Pirmann S; Teleanu V; Renner M; Andresen C; Köhler BC; Aybey B; Bauer S; Siveke JT; Hamacher R; Folprecht G; Richter S; Schröck E; Brandts CH; Ahrens M; Hohenberger P; Egerer G; Kindler T; Boerries M; Illert AL; von Bubnoff N; Apostolidis L; Jost PJ; Westphalen CB; Weichert W; Keilholz U; Klauschen F; Beck K; Winter U; Richter D; Möhrmann L; Bitzer M; Schulze-Osthoff K; Brors B; Mechtersheimer G; Kreutzfeldt S; Heining C; Lipka DB; Stenzinger A; Schlenk RF; Horak P; Glimm H; Hübschmann D; Fröhling S
    Eur J Cancer; 2022 Sep; 172():107-118. PubMed ID: 35763870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
    Huang PW; Chou WC; Shen WC; Hung CY; Huang KG; Su YL; Lu CH; Liu CT; Chang YS; Liau CT
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):353-360. PubMed ID: 29900662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial.
    Cho HJ; Yun KH; Shin SJ; Lee YH; Kim SH; Baek W; Han YD; Kim SK; Ryu HJ; Lee J; Cho I; Go H; Ko J; Jung I; Jeon MK; Rha SY; Kim HS
    Nat Commun; 2024 Jan; 15(1):685. PubMed ID: 38263321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
    Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
    Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
    Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
    Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    Bupathi M; Hays JL; Chen JL
    PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
    Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B
    J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
    Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
    Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
    Kobayashi H; Okuma T; Oka H; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Sato K; Abe S; Kawano H; Goto T; Tanaka S
    Int J Clin Oncol; 2018 Apr; 23(2):368-374. PubMed ID: 29086877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
    Sharma A; Kataria B; Biswas B; Bakhshi S; Pushpam D
    J Oncol Pharm Pract; 2022 Apr; 28(3):560-568. PubMed ID: 33719725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib in the treatment of soft tissue sarcoma.
    Schöffski P
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
    van der Graaf WT; Blay JY; Chawla SP; Kim DW; Bui-Nguyen B; Casali PG; Schöffski P; Aglietta M; Staddon AP; Beppu Y; Le Cesne A; Gelderblom H; Judson IR; Araki N; Ouali M; Marreaud S; Hodge R; Dewji MR; Coens C; Demetri GD; Fletcher CD; Dei Tos AP; Hohenberger P; ;
    Lancet; 2012 May; 379(9829):1879-86. PubMed ID: 22595799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.